Lymphoma Canada is conducting a survey of CLL patients with experience with idelalisib (Zydelig) to appeal to Canadian governments to provide funding for this treatment in Canada.
Lymphoma Canada is conducting a survey of CLL patients with experience with idelalisib (Zydelig) to appeal to Canadian governments to provide funding for this treatment in Canada.
Idelalisib (Zydelig) has been approved by the FDA and the European Medicines Agency. Canadians are also trying to gain access to this treatment. You don’t need to live in Canada to complete this survey.
Lymphoma Canada is preparing a submission to the pan-Canadian Oncology Drug Review (pCODR) for:
- idelalisib (Zydelig) in combination with rituximab for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL).
By responding to our survey, you will provide us with the patient input required for the submission. pCODR uses this information in the submission to help them make recommendations to the provinces and territories regarding funding for new drugs.
BY COMPLETING THE SURVEY, YOU WERE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS NEW TREATMENT IN CANADA.
This survey is now closed.
